Skip to main content
OpenTrials
Completed

NCT Number: NCT06172218

AM for Refractory Achilles Tendinopathy

To evaluate outcomes after use of micronized amniotic membrane to replace or supplement damaged or inadequate integumental tissue in patients with "chronic" insertional or non-insertional Achilles tendinopathy that remains refractory to standard care. Outcomes between a control and treatment group in this pilot study will be used to devise a multi-center study with larger sample size.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

North Park Podiatry

San Diego, California, 92104, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 64 years old
  • BMI ≤ 40 kg/m2
  • Subject has been diagnosed with unilateral Achilles tendinopathy (based on investigator assessment using ultrasound) of at least 3 months duration
  • History of having attempted a physical therapy for Achilles tendinopathy which must have included at least 6 weeks of eccentric exercise, alone or in addition to other non-surgical therapies
  • VISA-A score for the target tendon ≥40 and ≤60 at screening
  • Subject is willing to comply with all study procedures
  • Willing to sign a written informed consent to participate
  • Able to follow study instructions, with the intention of completing all required visits

Exclusion criteria

  • Planned surgical procedure below knee of the targeted extremity during study period
  • Patient has previously received an injection for this injury within the past 2 months
  • Major lower limb amputation of the contralateral leg
  • A medical condition, or a personal situation, which in the principal investigator's opinion, is not appropriate for participation in the trial
  • Osteoarthritis, chronic low back pain, fibromyalgia or any other condition that may affect the responses on the VISA-A
  • HIV infection, Hepatitis B or C infection, tuberculosis, COVID-19, cellulitis or any other active infection
  • Cognitive impairment, mental illness, neuroses, or untreated depression that would preclude understanding or reliably completing the patient reported outcome measures
  • Peritendinopathy, paratenonitis, partial tear or tendon rupture of the affected tendon
  • Subject has hindfoot deformities on the targeted extremity
  • Plantar fasciitis, calcaneal bursitis, Sever's disease, retrocalcaneal exostosis (Mulholland deformity, Haglund's deformity), enthesophytes, myofascial pain referral, posterior ankle impingement, os trigonum syndrome, tenosynovitis or dislocation of the peroneal or other plantar flexor tendons, an accessory soleus muscle, irritation or neuroma of the sural nerve, or systemic inflammatory disease
  • Leg length discrepancy, hyperpronation, varus deformity of the forefoot, pes cavus or limited mobility of the subtalar joint
  • Prior surgical intervention to the affected tendon
  • Current use of vitamins or herbal supplements
  • Current use of opioids, midazolam, gabapentin, pregabalin or ketamine
  • Compensable disability or work injury, ongoing litigation, or ongoing chiropractic care
  • Current use of systemic immunosuppressive medications, chemotherapy, or history of organ transplant (kidney, heart, lung)
  • Pregnancy and women who are expecting to be pregnant
  • Current enrollment in another interventional drug or device study or participation in such a study within 30 days of anticipated entry into this study

Treatment and study plan

Flo

Other

sterile, micronized human amniotic membrane product derived from placenta and umbilical cord

Saline

Other

sterile, preservative free 0.9% NaCl

Primary outcomes

  1. Change in Achilles pain

    Time frame: 30 days

    A score of 0 is considered no pain while a score of 10 is considered very severe pain

Secondary outcomes

  1. Change from Baseline in NRS score

    Time frame: over 3 months

    A score of 0 is considered no pain while a score of 10 is considered very severe pain

  2. Change from Baseline in VISA-A score

    Time frame: over 3 months

  3. Proportion of responders based on change in VISA-A score

    Time frame: over 3 months

    20 points as a threshold for assignment of responder status

  4. Proportion of complete pain relief

    Time frame: over 3 months

    pain score of 0

  5. Time to complete pain relief

    Time frame: over 3 months

    pain score of 0

  6. Proportion of subjects that respond feeling at least better and satisfied

    Time frame: 3 months

    patient satisfaction survey

Sponsors and collaborators

Lead sponsor

North Park Podiatry

Other

Registry information

Official study title

Prospective, Randomized Controlled Pilot Study Assessing Micronized Amniotic Membrane and Umbilical Cord Particulate in Patients With Symptomatic and Refractory Achilles Tendinopathy

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Dec 15, 2023
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.